Welcome to our dedicated page for Humacyte news (Ticker: HUMA), a resource for investors and traders seeking the latest updates and insights on Humacyte stock.
Humacyte, Inc. (Nasdaq: HUMA) is a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale. Its news flow centers on Symvess, an FDA-approved acellular tissue engineered vessel (ATEV™) for extremity arterial injury when autologous vein graft is not feasible, and on the broader clinical and regulatory progress of its ATEV pipeline.
On this page, readers can follow HUMA news related to vascular trauma, hemodialysis access, peripheral artery disease, and other vascular indications where Humacyte’s acellular tissue engineered vessels are being studied. Company announcements frequently cover clinical trial readouts, such as Phase 2/3 and Phase 3 data in trauma and dialysis access, long-term safety and efficacy publications in peer-reviewed journals, and presentations at major medical meetings including the VEITHsymposium and the American Society of Nephrology’s Kidney Week.
Humacyte also issues updates on healthcare economics analyses in extremity arterial injury, highlighting the cost impact of complications like amputation and conduit infection and positioning Symvess as an alternative when vein is not feasible. Additional news items describe humanitarian and real-world use of Symvess in wartime vascular injuries, as well as outcomes in hospital-acquired vascular complications and high-risk patient subgroups.
Investors and clinicians can use this HUMA news feed to track regulatory milestones, such as the FDA approval of the ATEV in vascular trauma, RMAT and Fast Track designations, and planned marketing authorization applications in new territories. Financial and corporate updates, including credit facilities, registered offerings, and sales agreements, are also reported through company press releases and Form 8-K filings. Bookmark this page for an organized view of Humacyte’s latest disclosures on its bioengineered tissue platform, commercial launch activities for Symvess, and ongoing pipeline development.
Humacyte (Nasdaq: HUMA) will release fourth quarter and year‑end financial results for the period ended December 31, 2025 on March 27, 2026, and will host a webcast and conference call at 8:00 a.m. ET to provide a corporate and financial update.
The company emphasizes its commercial‑stage biotechnology platform and notes FDA approval of Symvess (ATEV) for vascular trauma in December 2024 and ongoing late‑stage trials in AV access and PAD.
Humacyte (Nasdaq: HUMA) received a binding minimum purchase commitment of $1.475 million for Symvess to support a clinical evaluation and outreach program in hospitals in the Kingdom of Saudi Arabia (KSA), announced March 19, 2026.
Humacyte will provide training personnel, will not negotiate commercialization rights in the KSA with other parties through July 2, 2026, and is negotiating a potential joint venture and license to commercialize Symvess in the KSA. Symvess remains investigational for uses beyond its FDA-approved extremity vascular trauma indication.
Humacyte (Nasdaq: HUMA) entered a registered direct offering to sell 25,000,000 shares, expected to raise gross proceeds of $20.0 million, with closing on or about March 20, 2026.
Proceeds are intended to fund commercialization of Symvess for vascular trauma, a BLA supplement filing and the upcoming Phase 3 hemodialysis read-out, pipeline development, and general corporate purposes.
Humacyte (Nasdaq: HUMA) submitted a Marketing Authorization Application (MAA) to the Israel Ministry of Health for Symvess, its acellular tissue engineered vessel for extremity arterial trauma repair, on March 17, 2026.
Humacyte is also pursuing hospital-by-hospital access in Israel before approval and plans broader Middle East expansion; clinical data cited include a retrospective 16-patient wartime series with 100% survival, zero amputations and zero conduit infections.
Humacyte (Nasdaq: HUMA) said its management team will participate in investor conferences in March 2026. Presentations are scheduled at the TD Cowen 46th Annual Healthcare Conference on March 4, 2026 at 10:30–11:00 AM ET and a Barclays 28th Annual Global Healthcare fireside chat at 1:00–1:25 PM ET. Both sessions will be available via webcast.
Humacyte (Nasdaq: HUMA) presented 36-month V005 trial results for Symvess at the VESS Annual Winter Meeting on Feb 18, 2026. Symvess showed 92.9% infection-free rate from months 3–36, 87.3% limb salvage at 12 months and durable vessel diameter with no dilatation or narrowing through 36 months.
No conduit-related deaths or spontaneous structural failures were reported; three conduit infections occurred overall.
Humacyte (Nasdaq: HUMA) said the FY2026 U.S. Department of Defense appropriations include targeted funding to support procurement and evaluation of biologic vascular repair technologies for traumatic extremity arterial injuries when autologous vein grafting is not feasible.
Symvess is described as the only human-derived bioengineered blood vessel approved by the FDA; the release highlights a retrospective battlefield study of 16 patients with 100% survival, zero amputations, and zero conduit infections. Safety risks, including graft rupture, anastomotic failure, and thrombosis, are noted with boxed warning language and recommended antiplatelet therapy.
Humacyte (Nasdaq: HUMA) released a five-year retrospective analysis of hospital charges and payer costs for extremity arterial injury (2018–2023). The average initial hospital charge was $316,600 per patient; graft infection and amputation raised charges by about $589,921 and $492,986, respectively, while average reimbursed costs were far lower ($84,598 for infection, $116,611 for amputation). 26% of repairs used conduits other than autologous vein. Humacyte highlights Symvess as an off-the-shelf biologic conduit with markedly lower infection and amputation rates versus historical controls and reports positive three-year V005 Phase 2/3 results supporting limb salvage benefits.
Humacyte (Nasdaq: HUMA) plans to file a Marketing Authorization Application (MAA) with the Israel Ministry of Health for Symvess (acellular tissue engineered vessel) for arterial trauma repair in Q1 2026. The company expects a 120 working-day review period, citing existing FDA approval of Symvess. Humacyte is coordinating with Israeli surgeons who participated in the V005 Phase 2/3 trial and who have requested product access.
Humacyte said recently published positive three-year V005 results provide the first prospective long-term data for traumatic arterial repair using an off-the-shelf biologic conduit; Symvess is designed for immediate availability and has shown low infection rates and high limb-salvage rates in trauma settings.
Humacyte (Nasdaq: HUMA) announced publication (Dec 22, 2025) of long-term results for Symvess in the Journal of Vascular Surgery Cases, Innovations and Techniques.
The prospective V005 Phase 2/3 study followed 54 extremity arterial trauma patients up to 36 months. Key findings: infection-free rate 92.9% from months 3–36, limb salvage 87.3% at 12 months and 82.5% at 24 months, only three conduit infections, and no spontaneous ruptures or unprovoked structural failures attributed to Symvess.
The device is indicated when urgent revascularization is needed and autologous vein graft is not feasible; prescribing information includes a boxed warning on graft failure and recommendations for antiplatelet therapy.